COMMUNIQUÉS West-GlobeNewswire

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
23/05/2025
WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA ® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer [...]
Sol-Gel Reports First Quarter 2025 Results
23/05/2025
NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd . (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. [...]
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025
23/05/2025
Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast cancer patients, with no treatment-related discontinuations Successful completion of the [...]
Major shareholder notification – BlackRock, Inc.
23/05/2025
GN Store Nord A/S hereby announces that on May 22, 2025, pursuant to Section 38(1) and Section 39(1) of the Danish Capital Markets Act, it received a notification from BlackRock, Inc. stating that on May 21, 2025, [...]
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
23/05/2025
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European Commission expected in the [...]
Safe Shot to Capitalize on Yerbae’s Strong Retail Presence & Distributor Network Following Acquisition
23/05/2025
Acquisition expected to increase Safety Shot annual revenue by 1000 percent over 2024 SCOTTSDALE, Ariz., May 23, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc . (Nasdaq: SHOT) (“SHOT”, "Safety Shot”, or the “Company”), a [...]
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
23/05/2025
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, [...]
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
23/05/2025
COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its [...]
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
23/05/2025
Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with IMNN-001 and standard of [...]
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
23/05/2025
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for [...]
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting
23/05/2025
Study Demonstrated 87% Overall Response Rate in Metastatic Prostate Cancer Patients Treated with SYNC-T, a First-in-Class In Situ Personalized Immunotherapy Platform Abstract published on podium presentation that will [...]
Tilray Medical introduit Good Supply, la marque emblématique de cannabis canadienne, en Allemagne
23/05/2025
NEUMÜNSTER, Allemagne, 23 mai 2025 (GLOBE NEWSWIRE) -- Tilray Medical (« Tilray »), une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et un leader mondial du cannabis thérapeutique qui permet aux [...]
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
23/05/2025
Positive recommendation based on phase III INAVO120 data showing Itovebi TM (inavolisib) in combination with palbociclib and fulvestrant more than doubled progression-free survival in the first-line setting 1 The [...]
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
23/05/2025
– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – LOS ANGELES, CA, May 23, [...]
Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market
23/05/2025
ORION CORPORATION PRESS RELEASE 23 MAY 2025 at 12.40 EEST Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market Orion Corporation and Shilpa Biocare Private Limited, a fully- [...]
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
23/05/2025
ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today [...]
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
23/05/2025
NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
23/05/2025
DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly [...]
OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours
23/05/2025
OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours sur la modulation de l’immunité innée et l’activité antitumorale via le [...]

Pages